FDA Panel Votes to Add BPC-157 to Compounding List, Sending Hims & Hers Shares Up 7%

@thelonginvest

Peptides

@thelonginvest

$HIMS HERE WE GO

@thelonginvest

Peptides $HIMS

@wallstengine

$HIMS & Hers shares are trading higher after an FDA advisory panel recommended adding BPC-157 to the 503A compounding list, potentially widening access through licensed pharmacies.

@thelonginvest

I can already see the messages coming in ‘Is it too late to buy $HIMS?’ No

@thelonginvest

RT @himshouse: 🚨 FDA PEPTIDE PANEL VOTES 'YES' ON BPC-157 8 YES 6 NO 1 ABSTAIN $HIMS

@thelonginvest

$HIMS It was always about peptides

@maxmarchione

Voting on BPC-157 at the FDA peptide hearing is happening right now

@stocksavvyshay

$HIMS jumps more than 7% after an FDA panel recommends adding BPC-157 to the 503A compounding list potentially opening a new peptide category. The opportunity fits Hims existing telehealth, compounding and customer acquisition engine. http

@thelonginvest

$HIMS to $100 $ASTS to $360 $OSCR to $66 $UNH to $600 $ZETA to $66 $GRRR to $100 $ADUR to $40 $BABA to $360 $ETH $9200 There’s your portfolio Weather any storm Sit back and relax

@polymarketmoney

BREAKING: Hims & Hers scores a major win as an FDA panel backs BPC-157 for the 503A compounding list.

@maxmarchione

The FDA peptide panel just voted YES on BPC-157. The peptide era is here.

@vestexchange

$HIMS is up around 6% today, rebounding from a three-session slide ahead of the FDA's July 24 advisory hearing on compounded peptides, the key near-term item for its weight-loss and wellness offering. Recent target hikes from BofA, Canacco